Affimed puts on hold cancer drug trial after patient death
New Delhi: Drug Developer Affimed N.V. has put on hold the testing of its experimental cancer drug following the death of a patient and two life-threatening events.
The company's shares slumped 25 per cent to $3.82 in after-market trading.
Affirmed is testing the drug, AFM11, for treatment of acute lymphoblastic leukaemia and non-Hodgkin lymphoma in two separate early-stage trials.
The patient death occurred in the acute lymphoblastic leukaemia drug trial, while the life-threatening events took place in the non-Hodgkin lymphoma study.
Thirty-three patients have been treated in the two early-stage studies, the company said.
Affirmed said it was working with global health authorities, the safety monitoring committees and the studies' clinical investigators to review the events and will update on AFM11 after completing the evaluation.
The clinical hold would not affect the company's other ongoing experimental cancer drug studies, Affirmed said.
Accute leukaemiaAffimedAffimed N.V.AFM11hold cancer drug trialleukaemia drug triallymphoblastic leukaemialymphoblastic leukaemia drug trialNon-Hodgkin Lymphoma
Source : ReutersMedical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Next Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd